

DIN EN ISO 20916:2024-07 (E)

In vitro diagnostic medical devices - Clinical performance studies using specimens from human subjects - Good study practice (ISO 20916:2019)

| Contents | | Page |
|---|--|-------------|
| European foreword | | 4 |
| Annex ZA (informative) Relationship between this European Standard the General Safety and Performance Requirements of Regulation (EU) 2017/746 aimed to be covered | | 5 |
| Foreword | | 9 |
| Introduction | | 10 |
| 1 | Scope | 12 |
| 2 | Normative references | 12 |
| 3 | Terms and definitions | 13 |
| 4 | Ethical considerations | 22 |
| 4.1 | General..... | 22 |
| 4.2 | Improper influence or inducement..... | 22 |
| 4.3 | Responsibilities..... | 22 |
| 4.4 | Ethics committee involvement..... | 22 |
| 4.5 | Informed consent..... | 23 |
| 5 | Clinical performance study planning | 23 |
| 5.1 | General..... | 23 |
| 5.2 | Risk evaluation..... | 24 |
| 5.3 | Design of the clinical performance study..... | 25 |
| 5.4 | Investigator brochure..... | 25 |
| 5.5 | Clinical Performance Study Protocol (CPSP)..... | 26 |
| 5.5.1 | General..... | 26 |
| 5.5.2 | Principal investigator responsibilities..... | 26 |
| 5.5.3 | Contents of the CPSP..... | 27 |
| 5.6 | Case report forms..... | 30 |
| 5.7 | Recording of specimen information..... | 31 |
| 5.8 | Specimen accountability and integrity..... | 31 |
| 5.9 | Study site selection..... | 31 |
| 5.9.1 | Site qualification..... | 31 |
| 5.9.2 | Site assessment..... | 31 |
| 5.9.3 | Site selection..... | 31 |
| 5.10 | Monitoring plan..... | 32 |
| 5.11 | Agreements..... | 32 |
| 5.12 | Labelling..... | 32 |
| 6 | Study site initiation | 32 |
| 6.1 | General..... | 32 |
| 6.2 | Prerequisites..... | 33 |
| 6.3 | Training..... | 33 |
| 6.4 | Initiation of the study site..... | 33 |
| 7 | Clinical performance study conduct | 34 |
| 7.1 | General..... | 34 |
| 7.2 | Responsibilities of the sponsor..... | 34 |
| 7.3 | Study site monitoring..... | 34 |
| 7.3.1 | General..... | 34 |
| 7.3.2 | Routine monitoring..... | 34 |

| | | |
|---------------------|---|-----------|
| 7.3.3 | Monitoring reports..... | 35 |
| 7.4 | Security and confidentiality of data..... | 36 |
| 8 | Close-out of the clinical performance study..... | 36 |
| 8.1 | Close-out activities..... | 36 |
| 8.2 | Clinical performance study report..... | 36 |
| 8.3 | Document retention..... | 38 |
| 8.4 | Suspension or premature termination of the clinical performance study..... | 38 |
| 9 | Auditing..... | 39 |
| Annex A | (normative) Additional general requirements for certain studies..... | 40 |
| Annex B | (normative) Clinical performance study protocol (CPSP)..... | 43 |
| Annex C | (normative) Investigator brochure..... | 47 |
| Annex D | (normative) Clinical performance study report..... | 49 |
| Annex E | (normative) Communication with the ethics committee..... | 52 |
| Annex F | (normative) Informed consent..... | 54 |
| Annex G | (normative) Adverse event categorization..... | 58 |
| Annex H | (informative) Good clinical performance study documentation..... | 62 |
| Annex I | (informative) Auditing..... | 67 |
| Bibliography | | 68 |